Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

Read More Below

Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.
Read more

Contact Us

Thank you for your interest. Shire US Inc. welcomes your comments and questions.

Patients and Caregivers

If you would like additional information or need to report an adverse event, please contact the Shire Customer Service Center in the US at 1-800-828-2088, M-F 8:30 AM to 5:00 PM ET.

Health Care Professionals

Clinical inquiries: For further clinical information on Shire products, US doctors may call toll-free at 1-800-828-2088 or send an e-mail to medinfoglobal@shire.com.

Shire US Inc.
725 Chesterbrook Blvd.
Wayne, PA 19087